Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTESUNATE vs CAMOQUIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
Treatment of acute malaria caused by chloroquine-sensitive or chloroquine-resistant Plasmodium falciparum and other Plasmodium species,Treatment of uncomplicated malaria (FDA-approved),Off-label: intermittent preventive treatment of malaria in pregnancy (IPTp) in combination with sulfadoxine-pyrimethamine
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Primarily metabolized in the liver by CYP2C8 to the active metabolite desethylamodiaquine. Also undergoes N-oxidation and conjugation.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Mean Vd ~100–300 L/kg (extremely large due to extensive tissue sequestration, especially in erythrocytes and liver); indicates deep tissue distribution.
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
Oral bioavailability is approximately 75–85% (first-pass metabolism limited).
No dose adjustment required for any degree of renal impairment.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) due to risk of toxicity.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
5 mg base/kg (8.3 mg salt/kg) orally once weekly for prophylaxis; 10 mg base/kg (16.6 mg salt/kg) initially, followed by 5 mg base/kg at 6, 24, and 48 hours for treatment.
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
Use with caution; consider lower initial doses and monitor for QT prolongation and neuropsychiatric effects due to age-related changes in clearance.
None.
Amodiaquine hydrochloride is associated with hepatotoxicity and agranulocytosis. Use is contraindicated in patients with previous adverse reactions to amodiaquine. Prolonged use for prophylaxis is not recommended due to risk of severe hepatic injury and blood dyscrasias.
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
Monitor liver function tests; discontinue if signs of hepatotoxicity (elevated transaminases, jaundice). Risk of agranulocytosis, neutropenia; monitor CBC. Caution in patients with G6PD deficiency (risk of hemolysis). Can cause QT prolongation; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Reduce dose in severe hepatic impairment. Use in pregnancy only if potential benefit outweighs risk (no adequate studies).
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
Hypersensitivity to amodiaquine or other 4-aminoquinolines (e.g., chloroquine); history of hepatic disease or blood dyscrasias (e.g., agranulocytosis, neutropenia) associated with amodiaquine; concomitant use with hepatotoxic drugs or drugs known to cause agranulocytosis; patients with known G6PD deficiency (relative, use with caution).
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
No specific food restrictions; however, administration with fatty meals may enhance absorption. Avoid grapefruit juice due to potential CYP2C8 inhibition. Maintain adequate hydration and caloric intake.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Generally considered safe for malaria treatment; no evidence of increased malformations. Overall risk category C: Risk cannot be ruled out.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
Excreted in breast milk in small amounts. M/P ratio not established. Use with caution, especially in infants with G6PD deficiency. The WHO considers amodiaquine compatible with breastfeeding during malaria treatment.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
No specific dose adjustment required in pregnancy; standard dosing recommended for malaria treatment (based on weight). Pharmacokinetic changes in pregnancy (increased volume of distribution) do not necessitate dose modification.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
Camoquin hydrochloride (amodiaquine) is an antimalarial agent related to chloroquine. It is active against erythrocytic stages of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. Not effective against exo-erythrocytic forms. Hepatic metabolism via CYP2C8; genetic variants may affect toxicity. Monitor for hepatotoxicity and agranulocytosis, especially with prolonged use. Contraindicated in patients with liver disease or history of psychosis. Use with caution in G6PD deficiency due to risk of hemolysis.
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
Take exactly as prescribed; do not stop early even if feeling better.,May cause nausea; taking with food or milk can help reduce stomach upset.,Avoid alcohol while on this medication due to increased risk of hepatotoxicity.,Report any yellowing of skin or eyes, dark urine, severe fatigue, or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not take with fever or other antimalarials unless directed by your physician.
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTESUNATE vs CAMOQUIN HYDROCHLORIDE, answered by our medical review team.
ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. CAMOQUIN HYDROCHLORIDE is a Antimalarial that works by Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTESUNATE and CAMOQUIN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. The standard adult dose of CAMOQUIN HYDROCHLORIDE is: 600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTESUNATE and CAMOQUIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. CAMOQUIN HYDROCHLORIDE is classified as Category C. First trimester: Amodiaquine (CAMOQUIN HYDROCHLORIDE) is not recommended due to limited data but animal studies show no teratogenicity at therapeutic doses. Second/third trimester:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.